Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829185 | 0.85 | SLC16A1 (0.41) | SLC16A1ADORA2BHPDABCB11CYP3A4 | |
| SCHEMBL3832025 | 0.82 | ADORA2B (0.40) | SLC16A1ADORA2BHPDKMT2A | |
| SCHEMBL3828035 | 0.80 | SLC16A1 (0.47) | SLC16A1ABCB11CYP3A4CYP2C9 | |
| SCHEMBL5096911 | 0.77 | SLC16A1 (0.44) | SLC16A1ABCB11CYP3A4CYP2C9 | |
| SCHEMBL4840916 | 0.76 | SLC16A1 (0.51) | SLC16A1CYP3A4CYP2C9 | |
| SCHEMBL5106235 | 0.76 | NOTUM (0.37) | HPDKMT2A | |
| SCHEMBL5096915 | 0.75 | SLC16A1 (0.41) | SLC16A1ABCB11CYP3A4CYP2C9 | |
| SCHEMBL3855826 | 0.74 | POLB (0.31) | — | |
| SCHEMBL5106763 | 0.74 | SLC16A1 (0.46) | SLC16A1KMT2AABCB11CYP3A4CYP2C9 | |
| SCHEMBL3834031 | 0.74 | SLC16A1 (0.53) | SLC16A1HPDKMT2AABCB11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-7393854-B2 | Thienopyrimidinedinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-07-01 | — | — | US | disclosed |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | SLC16A1 4627/4885ADORA2B 18/4885HPD 1348/4885 |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | TBXA2R, PTGER2, TBXAS1 | SLC16A1 4795/4885ADORA2B 15/4885HPD 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.